Gene therapy

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy #Webinar

Webinar: Adeno-associated virus vectors for gene therapy

In a webinar on 5 September, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. The event is hosted by DDW and supported by Thermo Fisher Scientific. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#News

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy

Quantitative analysis of full and empty particles in adeno-associated virus vectors for gene therapy

In this event, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, presents his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. In recent years, AAV vectors have been launched and are considered one of the main platforms for gene therapy, with more than 250 clinical… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

#AAV #Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Positive Phase I/II trial data for Duchenne gene therapy

New data has revealed a robust microdystrophin expression from a pivotal dose of gene therapy RGX-202 for Duchenne muscular dystrophy (Duchenne). RGX-202 is an investigational one-time AAV therapeutic designed to deliver a novel microdystrophin gene that includes key regions of the naturally occurring dystrophin gene. Read More

#News

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News

Human brain
#Cell and gene therapy #Cell therapy #Gene therapy #Neurodegenerative disorders #Neuroscience

Five cell and gene therapy advances in neurodegeneration

Neurodegenerative diseases have recently increased at an alarming rate due to the ageing global population. There are a number of cell and gene therapies (CGTs) currently being developed to address these increasingly prevalent conditions. Diana Spencer provides an overview. A neurorestorative treatment Asklepios BioPharmaceutical’s (AskBio’s) AB-1005 is an adeno-associated virus… Read More

#Exclusive Content

#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

New eBook: Creating opportunities from advanced therapies

Cell and gene therapies (CGTs) are the fastest growing area of therapeutics, with many preclinical and clinical programmes currently underway. While cancer is key target for CGTs, these advanced therapies are also under investigation to treat conditions as varied as asthma, multiple sclerosis, ophthalmological conditions like… Read More

#News

DDW Cell and gene therapy eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Cell & gene therapy: Creating opportunities from advanced therapies

This eBook explores the current challenges and opportunities in the cell and gene therapy (CGT) space, and the factors likely to influence this area of therapeutics in the future. Download this exclusive eBook to learn more about: How innovative approaches are taking CGTs from bench to bedside The importance of… Read More

#DDW eBooks #Intelligence

#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Guide #Market reporting

Podcast: The global innovation and the opportunity in CGTs

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers five articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The promise and growth of cell and gene therapies… Read More

#News

Gene therapy
#Award #Career #Gene therapy #Genetics / genomics #Vivet Therapeutics

Dr Gonzalez-Aseguinolaza recognised for gene therapy research

Dr Gloria Gonzalez-Aseguinolaza, Co-Founder & Chief Scientific Officer of Vivet Therapeutics, has been awarded the Rosalind Franklin Society (RFS) Special Award in Science given by Mary Ann Liebert, Inc. and the Rosalind Franklin Society. The award recognises Dr Gonzalez-Aseguinolaza’s remarkable contributions and dedication to advancing scientific… Read More

#News

Gene therapy
#Asklepios BioPharmaceutical #FDA #Gene therapy #MHRA #Neurodegenerative disorders #Parkinson's

US and UK fast track designations for Parkinson’s gene therapy

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 has also been awarded the innovative medicine designation, the Innovation Passport by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment… Read More

#News #Regulatory

#Breast cancer #Cancer research #DNA mutations #Epigenetics #Gene therapy #Oncology

New podcast shining a spotlight on cancer research developments

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The ‘dark matter’ behind cancer and Could this ‘Goldilocks’… Read More

#Cancer Research #News

siRNA
#Aptamer Group #Aptamers #AstraZeneca #Collaboration #Gene therapy #siRNA

AstraZeneca and Aptamer test liver delivery vehicles with siRNA

Aptamer Group and AstraZeneca have entered a collaboration agreement to evaluate Aptamer’s Optimer fibrotic liver delivery vehicles for the targeted delivery of small interfering RNA (siRNA). Following the encouraging results achieved to-date with Aptamer’s fibrotic liver delivery vehicles, the next phase of the research will explore the potential of the… Read More

#Business & Investment #News

#CRISPR #Gene editing #Gene therapy #Genetic engineering #Genetics / genomics

New DDW Highlights episode: 8 July 2024

The latest episode of the DDW Highlights podcast and vodcast is now available to listen to or watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The last few days have seen some interesting developments… Read More

#News

#CRISPR #Gene editing #Gene therapy #Genetic engineering #Genetics / genomics

This week in drug discovery (1-5 July) 

News round-up for 1-5 July by DDW Senior Digital Content Editor Diana Spencer. The last few days have seen some interesting developments related to gene editing, including the discovery of a new mechanism for genetic programming and evidence in favour of redosing CRISPR-based therapies, as well as significant… Read More

#News

MRI of the brain
#AviadoBio #Dementia #Gene therapy #Neurodegenerative disorders #Phase II trial

Gene therapy trial starts in early-onset dementia

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University in the US. ASPIRE-FTD is evaluating investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with… Read More

#News

RNA
#Circio Holding #circular RNAs #Gene therapy #Genetic diseases #In vivo #mRNA

How does circVec technology compare to conventional mRNA? 

Circio has announced updated in vivo data that demonstrates a substantial durability advantage of Circio’s circVec technology over conventional mRNA expression. In addition, Circio has undertaken sequence optimisation resulting in a new circVec 2.2 design.   “The circVec 2.1 design is performing very well in… Read More

#News